ECSS
UTHR icon

Eurizon Capital SGR SpA’s United Therapeutics UTHR Stock Holding History

Eurizon Capital SGR SpA’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.72M Sell
5,016
-1,641
-25% -$924K 0.01% 507
2026
Q1 		$3.95M Buy
6,657
+2,016
+43% +$1M 0.01% 446
2025
Q4 		$2.26M Buy
+4,641
New +$2.16M 0.01% 452

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Eurizon Capital SGR SpA's UTHR Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its United Therapeutics (UTHR) stake by 25% in Q2 2026, selling an estimated $924K and leaving 5,016 shares worth $2.72M. The position accounts for 0.01% of the portfolio, ranked #507.

Eurizon Capital SGR SpA first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.95M in Q1 2026. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Eurizon Capital SGR SpA held 5,016 shares of United Therapeutics worth $2.72M as of Q2 2026.
  • Eurizon Capital SGR SpA sold 1,641 United Therapeutics shares in Q2 2026, an estimated $924K.
  • United Therapeutics made up 0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #507 holding.
  • Eurizon Capital SGR SpA first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's United Therapeutics position peaked at $3.95M in Q1 2026.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.